Skip to main content
Autobound logo
Acumen Pharmaceuticals, Inc.SEC 10-Q

Acumen anticipates loss of emerging growth company status effective December 31, 2026

Read at SEC EDGAR

What happened

Acumen expects to cease qualifying as an emerging growth company as of December 31, 2026, ending its exemptions from certain reporting requirements including auditor attestation under SOX Section 404. This transition may require increased external spend on...

Source

Extracted by Autobound

From the Signal API record
Signal
SEC 10-Q

What this signalsFilings often name leadership changes, deals and spending plans.

Filed
Oct 26, 2026

More SEC 10-Q signals at other companies

The full record

From the Signal API record

Details

CIK
1576885
Accession number
0001628280-26-067276
Timeframe
Next quarter
Quarter
Q3
Filing year
2026
Fiscal year end
09/30
Period end date
Sep 30, 2026
Why it matters
GRC tools needed
Signal category
Risk

Extraction

Confidence
High
Relevance
70%
Sentiment
Negative
Detected
Oct 27, 2026
signal_type
sec-10q
signal_subtype
complianceBurden

Use this data

Get every SEC 10-Q signal for Acumen Pharmaceuticals, Inc. and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Acumen Pharmaceuticals, Inc. this week?”

    MCP setup guide

  2. Send it to your own tools

    The Signal API returns SEC 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

    Signal API

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Start Free1,000 free creditsUse it in Claude via MCP
Show the full JSONThe record on this page and the API request

GET /v1/signals/45387f4c-d067-4bee-8995-cb8a8971a427 returns this record as JSON. POST /v1/companies/enrich returns every signal for acumenpharm.com.

{
  "signal_id": "45387f4c-d067-4bee-8995-cb8a8971a427",
  "signal_type": "sec-10q",
  "signal_subtype": "complianceBurden",
  "detected_at": "2026-10-27T08:03:56.53+00:00",
  "company": {
    "name": "Acumen Pharmaceuticals, Inc.",
    "domain": "acumenpharm.com"
  },
  "data": {
    "detail": "Acumen expects to cease qualifying as an emerging growth company as of December 31, 2026, ending its exemptions from certain reporting requirements including auditor attestation under SOX Section 404. This transition may require increased external spend on accounting, audit, legal, and compliance advisory services.",
    "metrics": {
      "timeframe": "next_quarter"
    },
    "quarter": "Q3",
    "summary": "Acumen anticipates loss of emerging growth company status effective December 31, 2026",
    "relevance": 0.7,
    "sentiment": "negative",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/1576885/000162828026067276/abos-20260930.htm",
    "filing_date": "2026-10-26",
    "filing_year": 2026,
    "fiscal_year": 2026,
    "fiscal_year_end": "09/30",
    "period_end_date": "2026-09-30",
    "sales_relevance": "GRC tools needed",
    "signal_category": "risk"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.